Microbiology and Immunology

You are here

Home > Publications > Publications

Publications

Found 47 results
Author Title [ Type(Desc)] Year
Filters: Author is Moore, John P  [Clear All Filters]
Journal Article
Dey AK, David KB, Ray N, Ketas TJ, Klasse PJ, Doms RW, Moore JP.  2008.  N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus.. Virology. 372(1):187-200.
Van Voorhis WC, Adams JH, Adelfio R, Ahyong V, Akabas MH, Alano P, Alday A, Resto YAlemán, Alsibaee A, Alzualde A et al..  2016.  Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond.. PLoS Pathog. 12(7):e1005763.
Moore JP, Kuritzkes DR.  2009.  A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.. Curr Opin HIV AIDS. 4(2):118-24.
Pejchal R, Doores KJ, Walker LM, Khayat R, Huang P-S, Wang S-K, Stanfield RL, Julien J-P, Ramos A, Crispin M et al..  2011.  A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield.. Science. 334(6059):1097-103.
Veazey RS, Springer MS, Marx PA, Dufour J, Klasse PJohan, Moore JP.  2005.  Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor.. Nat Med. 11(12):1293-4.
Veazey RS, Klasse PJohan, Schader SM, Hu Q, Ketas TJ, Lu M, Marx PA, Dufour J, Colonno RJ, Shattock RJ et al..  2005.  Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion.. Nature. 438(7064):99-102.
Veazey RS, Ketas TJ, Dufour J, Moroney-Rasmussen T, Green LC, Klasse PJ, Moore JP.  2010.  Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor.. J Infect Dis. 202(5):739-44.
Anastassopoulou CG, Ketas TJ, Depetris RS, Thomas AM, Klasse PJohan, Moore JP.  2011.  Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41.. Virology. 413(1):47-59.
Anastassopoulou CG, Ketas TJ, Klasse PJohan, Moore JP.  2009.  Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41.. Proc Natl Acad Sci U S A. 106(13):5318-23.
Liu J, Deng Y, Li Q, Dey AK, Moore JP, Lu M.  2010.  Role of a putative gp41 dimerization domain in human immunodeficiency virus type 1 membrane fusion.. J Virol. 84(1):201-9.
Tsibris AMN, Pal U, Schure AL, Veazey RS, Kunstman KJ, Henrich TJ, Klasse PJ, Wolinsky SM, Kuritzkes DR, Moore JP.  2011.  SHIV-162P3 infection of rhesus macaques given maraviroc gel vaginally does not involve resistant viruses.. PLoS One. 6(12):e28047.
Dey AK, David KB, Klasse PJ, Moore JP.  2007.  Specific amino acids in the N-terminus of the gp41 ectodomain contribute to the stabilization of a soluble, cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1.. Virology. 360(1):199-208.
Melchers M, Matthews K, de Vries RP, Eggink D, van Montfort T, Bontjer I, van de Sandt C, David K, Berkhout B, Moore JP et al..  2011.  A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cells.. Retrovirology. 8:48.
Bontjer I, Melchers M, Eggink D, David K, Moore JP, Berkhout B, Sanders RW.  2010.  Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution.. J Biol Chem. 285(47):36456-70.
W Horne S, Johnson LM, Ketas TJ, Klasse PJohan, Lu M, Moore JP, Gellman SH.  2009.  Structural and biological mimicry of protein surface recognition by alpha/beta-peptide foldamers.. Proc Natl Acad Sci U S A. 106(35):14751-6.
Kang YKenneth, Andjelic S, Binley JM, Crooks ET, Franti M, Iyer SPrasad N, Donovan GP, Dey AK, Zhu P, Roux KH et al..  2009.  Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1.. Vaccine. 27(37):5120-32.
Liu J, Deng Y, Dey AK, Moore JP, Lu M.  2009.  Structure of the HIV-1 gp41 membrane-proximal ectodomain region in a putative prefusion conformation.. Biochemistry. 48(13):2915-23.
R Malcolm K, Veazey RS, Geer L, Lowry D, Fetherston SM, Murphy DJ, Boyd P, Major I, Shattock RJ, Klasse PJohan et al..  2012.  Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques.. Antimicrob Agents Chemother. 56(5):2251-8.
Melchers M, Bontjer I, Tong T, P Y Chung N, Klasse PJohan, Eggink D, Montefiori DC, Gentile M, Cerutti A, Olson WC et al..  2012.  Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses.. J Virol. 86(5):2488-500.
Harris A, Borgnia MJ, Shi D, Bartesaghi A, He H, Pejchal R, Kang YKenneth, Depetris R, Marozsan AJ, Sanders RW et al..  2011.  Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures.. Proc Natl Acad Sci U S A. 108(28):11440-5.
Veazey RS, Ketas TA, Klasse PJohan, Davison DK, Singletary M, Green LC, Greenberg ML, Moore JP.  2008.  Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249.. Proc Natl Acad Sci U S A. 105(30):10531-6.
Berro R, Sanders RW, Lu M, Klasse PJ, Moore JP.  2009.  Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry.. PLoS Pathog. 5(8):e1000548.